ArticleFrontiers in endocrinology2026
The correlation between the trajectory of plasma atherosclerosis-inducing index in the examination population and the risk of developing metabolic dysfunction-associated steatotic liver disease.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent metabolic disorder with rising global incidence and substantial clinical implications. The atherogenic index of plasma (AIP), a novel marker of lipid metabolism, has shown potential in predicting metabolic diseases, but its longitudinal association with MASLD remains unclear. Methods: This longitudinal study included 1,894 participants from the health examination database of the First Affiliated Hospital of Xi'an Jiaotong University (2020-2024). Group-based trajectory modeling (GBTM) identified three AIP trajectory patterns: low-stable, moderate-stable, and high-stable. Cox proportional hazards models were used to assess the association between AIP trajectories and incident MASLD, adjusting for demographic, lifestyle, and metabolic factors. Subgroup and sensitivity analyses were conducted to assess effect modification and robustness. Results: Three AIP trajectory patterns were identified: low-stable (33.7%), moderate-stable (49.1%), and high-stable (17.3%). Over a median follow-up of 2.97 years, the high-stable group exhibited a 2.23-fold increased risk of incident MASLD (adjusted HR = 2.23, 95% CI: 1.51-3.30; P < 0.001) compared with the low-stable group, even after adjusting for metabolic mediators including BMI and fasting glucose. The moderate-stable group also showed an increased risk (HR = 1.42, 95% CI: 1.02-1.98; P = 0.038). Subgroup analyses demonstrated consistent associations, with more pronounced effects among non-diabetic and non-hypertensive individuals. Sensitivity analyses further confirmed the robustness of these findings. Conclusions: Sustained high AIP levels are independently associated with an increased risk of MASLD. AIP trajectory monitoring may offer a valuable tool for early identification and targeted prevention of MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.